**Supplementary Table 2** Baseline characteristics of subjects in individual studies - Medications

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| First author, Year | ACE inhibitors (%) | Beta-blockers (%) | Nitrates (%) | Oral anticoagulants (%) |
| Madelaire *et al,* 2018 | 66.74 (ACEi or ARB) | 52.14 | - | 0 |
| Bermingham *et al,* 2014 - low dose aspirin | 83.71 | 84.84 | 55.81 | 45.54 |
| Bermingham *et al,* 2014 - high dose aspirin | 83.8 | 81.48 | 48.15 | 62.5 |
| Krumholz *et al,* 2001 | 64 | 23 | 59 | 26 |
| Cleland *et al,* 2004 | 91.05 | 11.05 | - | 5 |
| Al-Khadra *et al,* 1998 | - | 17.67 | 34.96 | 13.22 |
| Harjai *et al, 2003* | 100 | - | - | - |
| Harjai *et al*, 2001 | 100 | 17.46 | 47.09 | - |
| Aumegeat *et al*, 2003 | 100 | 24 | 41 | 35 |
| Chang *et al*, 2010 | 41.12 | 55.31 | 33.96 | 30.77 |
| Chin *et al*, 2016 | 80.42 | 86.59 | - | 17.98 |
| Pedone *et al*, 2005 | 0 | 4.43 | 49.8 | 21.55 |
| Khalil *et al,* 2018 – low dose aspirin | 68.05 | 50.9 | - | - |
| Guazzi *et al*, 2003 – low dose aspirin | 100 | 18.93 | 27.5 | 0 |
| Guazzi *et al*, 2003 – high dose aspirin | 100 | 19.06 | 28.09 | 0 |
| Masoudi *et al*, 2005 | 53 | 31 | - | 0 |